21 - 22 June 2018 / Barcelona, Spain

Agenda

The event agenda's time zone is CEST.

Thu
21 Jun 2018
08:30 – 09:15
Main hall
Registration

Please provide valid photo ID.

09:15 – 09:35
Auditorium
Institutional opening
  • Albert Barberà. Director General for Research and Innovation of Health, Government of Catalonia.President of the Delegate Commission, Biocat.
  • Roland Bugat, ONCONET SUDOE scientific coordinator, University Toulouse III Paul Sabatier. 
  • Lourdes Núñez. Director of Knowledge Transfer, Internationalization and Entrepreneurship, Fundación Pública Andaluza Parque Tecnológico de la Salud de Granada (PTS Granada). Onconet WP4 leader.
09:35 – 10:20
Auditorium
Keynote session: Translational cancer research

Joaquín Arribas. Scientific Director, Vall d'Hebron Institute of Oncology (VHIO).

10:20 – 13:00
Partnering Area
One2One meetings

Check this session if you want to offer availability during Thursday Morning 

10:20 – 11:50
Auditorium
Plenary session 1: Innovative therapeutic approaches in oncology

The knowledge of molecular mechanisms involved in cancer, contributes not only to a better understanding of the disease but also to the development of new prognostic markers and targeted cancer therapies contributing to a more effective precision medicine. Current approaches in medical practice are currently based on the concept of cancer precision/personalized medicine. They follow the principle of the identification of therapeutic response biomarkers, or the identification of those at risk of drug unbearable side effects, or useless therapeutical benefit.

Lately, the great advance in cancer therapy is sustained by immunotherapy, now considered the “fifth pillar” of cancer treatment. An emerging immunotherapy approach, called adoptive cell transfer (ACT) is also very promising. Again, in which concerns immune checkpoint therapy, there are many ongoing efforts to identify predictive biomarkers of response to immune checkpoint therapy.

Germline differences in immune genes and in host microbiome, the tumor mutational load as well as, other tumor microenvironment players are know very actively studied. Furthermore, research on nanotechnology has been capable of inducing selectively targeting cancer cells, enhancing the therapeutic efficacy of cancer chemotherapy agents, leading to better patient survival.

Chair: Ana Bela Sarmento. Group Leader at CIMAGO, Faculty of Medicine of the University of Coimbra.

Speakers:

  • Laura Soucek. Founder and Chief Scientific Officer, Peptomyc.
  • José Manuel Nascimento Costa. Director of University Clinic of Oncology, Faculty of Medicine of the University of Coimbra (FMUC).
  • Pedro Sánchez Rovira. Oncology Unit Director, Hospital de Jaén.
  • Antonio Viudez. Second Director, Hospital Complex of Navarre.
Break
11:50 – 12:20
Main hall
Coffee break
12:20 – 13:05
Auditorium
Plenary session 2 - Reimbursment and market access to oncology treatments

After cardiovascular disease, cancer is the most common cause of death in Europe. How to balance the access to oncological treatments and face with economic constraints is one of the most acute dilemmas that the health systems are currently facing. Oncologic treatments are known by their high research and production costs.

With awesome results in terms of survival among cancer patients in the last decades, several issues arise like divergences across EU members in outcomes and survival and  high variability in terms of access to oncologic treatments among patients in Europe.

The hurdles to overcome in terms of reimbursement and access varies widely and are constantly under public debate: different evaluation methods, variable pricing and reimbursement systems as well as  financial and or performance based agreements are on the sharp focus of the discussion.

This plenary session is expected to bring light on current but specially new approaches to cope with public funding and access of oncologic treatments: its added value,  role of patients and their expectations and  preferences  and how health systems are facing and proposing to cope within this dilemma in the mid-term.

Chair: Cristina Espinosa Tomé. Corporate Medical Director, Ferrer.

Speakers:

  • José Antonio Lopes Feio. Director of Pharmaceutical Services, Centro Hospitalar e Universitário de Coimbra (CHUC).
  • Caridad Pontes García. Lead of Pharmacotherapeutic Harmonization, Catalan Health Service (CatSalut).
Breakout sessions
13:15 – 13:45
Room A
Introductory session A I Needs of children and teenagers with cancer

The session chair will lay the groundwork for the brainstorming challenge session at 3.15 pm, introducing the topic, presenting future goals and solutions already explored.

Novel strategies to improve children’s cancer outcome will require a better understanding of the developmental process underlying the disease. Experience tells us that following the path of adult cancer discoveries has not helped children suffering from cancer. Therefore, disease-centered research is absolutely required.

Chair: Jaume Mora. Scientific Director of the Pediatric Hemato-Oncology, Hospital Sant Joan de Déu (SJD) Barcelona.

Moderator: Emilia Ventel. Project Manager, University Toulouse III - Paul Sabatier.

Breakout sessions
13:15 – 13:45
Room B
Introductory session B I Biomarkers and liquid biopsy for P4 oncology

In the current advent of the human genome landscape and powerful new sequencing technologies, a revolution in the biomarker field was anticipated in the oncology field. The reality is that the implementation and uptake of new biomarkers and technologies such as liquid biopsies are relatively slow owing to technical, biological and clinical limitations in conjunction with low value recognition. Whereas some technical updates have become a reality, the expected introduction of the personalized medicine paradigm has clashed with the need to address unmet medical needs. In this session we will introduce the topic, present current state of the art and discuss present future goals and already explored solutions. We will aim to respond to questions during the Brainstorming session.


Chair: Roger Gomis. ICREA Research Professor, Head of the Growth Control and Cancer Metastasis Lab, Institute for Research in Biomedicine (IRB Barcelona).

Moderator: Arantxa Ibarrola Segura. Project Manager, Navarrabiomed.

Breakout sessions
13:15 – 13:45
Room C
Introductory Session C I Telemedicine, mHealth and healthy habits for oncology patients

An increasing number of patients survive cancer. Telemedicine supports the use of medical, clinical and administrative information exchanged electronically from one site to another to improve a patient’s clinical health status. These exchanges should permit better patient management, an improvement in patient care/services and greater communication between patients and health specialists that eventually might turn into patient empowerment. E-health interventions have shown to be efficacious to decrease fat intake and increase fruit and vegetable intake, while other interventions centered in self-monitoring of body weight and nutrition/life styles related behaviors. E-Health literacy has become an up-to-date concept. Indeed, we need to acknowledge that internet and new technologies are “here for good” and health promotion needs to update its interventions for several health behaviours, with potential major benefits.

The session chair will lay the groundwork for the brainstorming challenge session at 3.15 pm, introducing the topic, presenting future goals and solutions already explored.


Chair: Paula Ravasco. Professor, University Hospital of Santa Maria - University of Lisbon - Centre for Interdisciplinary Research in Health of the Portuguese Catholic University.

Moderator: Mireia Félez. Project Manager for Onconet, Catalan Institute of Oncology (ICO).

Break
13:45 – 15:15
Main hall
LUNCH + POSTERS

The ONCO Emergence Forum features a poster session to foster the exchange of knowledge among participants. Posters will describe studies or best practices in oncology research or clinical practice.

Posters showcased have their quality reviewed by Onconet Emergence Forum Barcelona scientific committee 

15:00 – 17:40
Partnering Area
One2One meetings

Check this session if you want to offer availability during Thursday evening 

Breakout sessions
15:15 – 17:15
Room A
Brainstorming challenge A I Needs of children and teenagers with cancer

Join an exciting multidisciplinary discussion to identify future challenges and assess potential solutions. We will use discussion-based methodology and you will be able to interact with all 25 participants in the group. 

Why is that children and teenagers never develops prostate cancer, or stomach cancer or breast cancer?

How is that adult people never develops retinoblastoma, or hepatoblastoma, or any blastoma?

What is a pediatric tumor?  A 4 years old child with leukemia suffers the same process as a 45 years old woman with leukemia?

When are we biologically adults? Why is that the older we get the more cancer we develop? And so, why infants do develop tumors?

Do teenagers and young adults with cancer suffer from an adult-cancer based process or they suffer from a developmental-based process?

And importantly, does research (and drug development) for breast cancer (or lung, or prostate..) matters to children with cancer?

Why is it that no drug has ever been developed by the Pharmaceutical industry for any childhood tumor?

Attendants are strongly recommended to assist to the previous Introductory Session on Thursday 21 June, before the Brainstroming Challenge Session. In this Introductory Session chair will lay the groundwork for the brainstorming challenge session at 15.15 pm, introducing the topic, presenting future goals and solutions already explored.


Chair: Jaume Mora. Scientific director of the Oncology and Hematology Area, Sant Joan de Déu (SJD) Barcelona Children's Hospital.

Moderator: Emilia Ventel. Project Manager, University Toulouse III - Paul Sabatier.

Featured participants:

  • Lucas Moreno. Head of Clinical Trials Unit, Hospital Infantil Universitario Niño Jesús. 
Breakout sessions
15:15 – 17:15
Room B
Brainstorming Challenge B I Biomarkers and liquid biopsy for P4 oncology
  • Why has there been so little advance in the introduction of new biomarkers in oncology?
  • Is fundamental biology not aiming to address unmet medical needs? Do treatment response biomarkers truly exist?
  • Is the liquid biopsy the future? In  which settings/window opportunities? At what cost? 
  • How do the regulatory agencies influence/limit the development of new biomakers?
  • How do the all stakeholders view/perceive the inclusion of a biomarker? Threat or bonus?

Join an exciting multidisciplinary discussion to identify future challenges and assess potential solutions. We will use discussion-based methodology and you will be able to interact with all 25 participants in the group. 

Attendants are strongly recommended to assist to the previous Introductory Session on Thursday 21 June, before the Brainstroming Challenge Session. In this Introductory Session chair will lay the groundwork for the brainstorming challenge session at 15.15 pm, introducing the topic, presenting future goals and solutions already explored.


Chair: Roger Gomis. ICREA Research Professor, Head of the Growth Control and Cancer Metastasis Lab, Institute for Research in Biomedicine (IRB Barcelona).

Moderator: Arantxa Ibarrola Segura. Project Manager, Navarrabiomed.

Featured participants:

  • Pierre Cordelier. Research Director, Institut national de la santé et de la recherche médicale (INSERM).
  • David Guerrero-Setas. Principal investigator in cancer epigenetics research group, Navarrabiomed-FMS.
Breakout sessions
15:15 – 17:15
Room C
Brainstorming Challenge C I Telemedicine, mHealth and healthy habits for oncologic patients

Join an exciting multidisciplinary discussion to identify future challenges and assess potential solutions. We will use discussion-based methodology and you will be able to interact with all 25 participants in the group. 

Attendants are strongly recommended to assist to the previous Introductory Session on Thursday 21 June, before the Brainstroming Challenge Session. In this Introductory Session chair will lay the groundwork for the brainstorming challenge session at 15.15 pm, introducing the topic, presenting future goals and solutions already explored.

Chair: Paula Ravasco. Professor, University Hospital of Santa Maria - University of Lisbon - Centre for Interdisciplinary Research in Health of the Portuguese Catholic University, Portugal.

Moderator: Mireia Félez. Project Manager for Onconet, Catalan Institute of Oncology (ICO).

Featured Participants

  • Emmanuel Sicard. CEO, MHComm.
  • Juan Ignacio Arrarás. Principal Investigator in research group Quality of Life from oncology patients inside EORTC, Navarrabiomed-FMS.
  • Cristian Ochoa. Psycho-oncologist, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL).
  • Marta Gómez de Cedrón. Postdoctoral Researcher, IMDEA Research Institute on Food & Health Sciences.
15:15 – 16:15
Auditorium
Scientific session 1: Future omic tools in oncology: genomics bioinformatics and epigenetics

¿Target sequencing or whole genome? ¿Central cores for genomics or small units in each institution? ¿Is there life beyond illumina technologies? ¿A bioinformatician in each research group or bionformatics facility in each center? ¿How do we store the genomic information? ¿How do we share the genomic data? ¿Is it possible to have anonymous genomic information? ¿Ethics in genomics: do we communicate the genomic variants associated with human disease? ¿Which are the new technologies in genomics?  ¿What about single cell genomics? ¿And what’s the hype about machine learning? ¿Who will pay to obtain, store and analyze this genomic raw data? ¿Are we preparing the right professionals to deal with the new genomics era? ¿Are there difference in the way we deal with the different omics data: genomic, transcriptomic, epigenomics, epitranscriptomics?

 

These are the questions that will be discussed, and maybe answered, at the Scientific Session 1: Future omic tools in oncology: genomics bioinformatics and epigenetics.

Chair: Manel Esteller Badosa. ICREA Research Professor, IDIBELL, Bellvitge Biomedical Research Institute.

Speakers:

  • Enrique Carrillo. Head of Computational Biology Group, IMDEA Research Institute on Food & Health Sciences.
  • Miquel Angel Pujana. Director Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, IDIBELL. 
  • Pedro Carmona Sáez. Bioinformatics Unit Head, Center for Genomics and Oncological Research (GENyO).
  • David Gómez-Cabrero. Head of Bioinformatics Unit, Navarrabiomed-FMS.
16:15 – 17:15
Auditorium
Scientific session 2: Tumor micro environment in cancer progression

Cancer initiation and progression is intimately associated to changes in tumor microenvironment that aid and allow for tumor growth and evolution. Tumor microenvironment is not only important in defining cancer behavior and response to treatment but it can also be a direct target for anticancer treatment. This session will focus on the microenvironment and its relevance in cancer progression, with a specific focus on targeted therapies that modulate several different components of the tumor microenvironment to fight cancer.


Chair: Oriol Casanovas. Head of Tumor Angiogenesis Group, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL).

Speakers:

  • Luís Costa. Director of Oncology Division, Hospital de Santa Maria – Centro Hospitalar Lisboa Norte.
  • Juan Carlos Rodríguez Manzaneque. Proteases and Extracellular Matrix Group Leader, Centre for Genomics and Oncological Research (GENyO).



Break
17:15 – 17:45
Coffee break
17:45 – 18:15
Auditorium
Brainstorming wrap-up

Results from Brainstorming challenges will be presented by session chairs.

20:00 – 22:30
PRBB
Evening reception

Buses will be available from Fira Barcelona GranVia starting at 7.30 pm.

Return buses will be available from PRBB until 10.45 pm.

Participants must sign up for this session in advance in order to be able get on board the bus as well as to enter the reception venue. Event ID badge will be required to enter and stay the reception venue.

Fri
22 Jun 2018
09:30 – 09:40
Auditorium
Word of welcome

Núria Martí. Director of Innovation, Biocat.

09:40 – 11:40
Partnering Area
One2One meetings

Check this session if you want to offer partnering availability during Friday Morning

09:40 – 11:00
Auditorium
Plenary session 3 - How patients, researchers and clinicians can go into policymaking to foster RRI

RRI stands for Responsible Research and Innovation, “a transparent, interactive process by which societal actors and innovators become mutually responsive to each other with a view on the (ethical) acceptability, sustainability and societal desirability of the innovation process and its products” (von Schomberg, EC 2011).

The alignment of research, innovation and healthcare policies is essential for embedding in our society scientific and technological advances to fight cancer. Different stakeholders, researchers, managers, clinicians and patient representatives, will present diversity of experiences in shaping RRI policies and initiatives. The audience will engage in discussing about challenges and opportunities, needs, objectives and means to achieve responsible cancer R&I.  

Chair: Michela Bertero. Head of Internationalization and Scientific Affairs, Centre for Genomic Regulation (CRG). Orion Project.

Speakers:

  • Pastora Martínez. Vice President for Globalization and Cooperation, Open University of Catalonia (UOC).
  • José Expósito Hernández. Director of the Oncology Unit, Virgen de las Nieves University Hospital.
  • Fernando Regateiro. Director of Administrative Council, Centro Hospitalar e Universitário de Coimbra (CHUC).
  • Concepción Biurrun. Treasurer and representative, Saray (Asociación Navarra de Cancer de Mama).


    Break
    11:00 – 11:40
    Main hall
    Coffee break
    11:40 – 13:30
    Auditorium
    TECH TRANSFER COMPETITION

    The TECH TRANSFER COMPETITION features 12 cherry-picked entrepreneurs, TTO or principal investigators that are developing new technology from a research entity that is ready to be licensed or has begun development through a spin-off. 

    Selected participants will present their innovative projects in a 6-minute pitch to an experienced panel of judges.

    Presented by: Roi Villar. Head of Internationalization, Biocat.

    Panel of judges:

    • Núria Martí. Director of Innovation, Biocat.
    • Marc Criton. Responsable Projects & Business Development, Pôle Santé, SATT AxLR.
    • Lourdes Núñez Müller. Director of Knowledge Transfer, Internationalization and Entrepreneurship, Fundación Pública Andaluza Parque Tecnológico de la Salud de Granada (PTS Granada).

    13:30 – 14:00
    Auditorium
    INSTITUTIONAL CLOSING

    This session will feature the award ceremony for the OncoTRANSFER COMPETITION.

    • Jordi Naval. Director of Strategy, Biocat.
    • Roland Bugat. Director of Onco-Résonanece, Institut Universitaire du Cancer de Toulouse Oncopole (IUCT Oncopole). Onconet Scientific Coordinator.
    • Lourdes Núñez. Director of Knowledge Transfer, Internationalization and Entrepreneurship, Fundación Pública Andaluza Parque Tecnológico de la Salud de Granada (PTS Granada). Onconet WP4 leader.